Guitao Wang, Ph.D.
VP, G.M. Assistant, VP of Research Institute
Guitao Wang leads the R&D project management and pipeline development of Coherent Biopharma. Prior, he served as R&D team leader in Novartis, SynTheAll, and XWLab. He has more than 10 years experiences in the drug design, synthesis, evaluation and process development. He lead more than 20 projects of drug R&D and IND enabling. Dr. Wang holds Ph. D. in organic chemistry, Shanghai institute of organic chemistry, CAS, and B. S. in chemistry and biology, Wuhan university.
Jun Shao, Ph.D.
U.S. GM & COO
Jun Shao is responsible for overseeing the company's operations in the US, regulatory submissions and registrations, GMP and GCP quality assurance systems, clinical drug supply and logistics, later-stage product pipeline development. Prior to joining the company, Dr. Shao held R&D and Management positions in several US and Chinese leading pharmaceutical companies, including Abbott laboratories, Procter and Gamble Pharmaceuticals, eVenus Pharmaceutical Laboratories (Jiangsu Hengrui’s US subsidiary), and Zhejiang Hisun Pharmaceutical. With over 30 years of academic and industry experiences in China and the US, Dr. Shao has a strong background in drug research and development, manufacturing, regulatory affairs, and quality assurance. He has successfully filed over a dozen of IND/ANDA submissions with the US FDA and led passing numerous regulatory GMP inspections by Chinese NMPA, US FDA, EMA, WHO and Health Canada.
Robert Huang，PhD & MBA
Founder，Chair and CEO
A serial entrepreneur with over 30 years of experience in the pharmaceutical and biotech industries, Dr. Robert Huang has held roles with increasing responsibilities, including post-doctoral fellow, group head, director of business development, senior director of strategy and corporate development, and president at Abbott Labs, Millipore, Tularik, Applied Biosystems, and Abgent, respectively. He is the founder of iBioSource in San Francisco and Suzhou in 2011, and Coherent Biopharma in 2016. Dr. Huang earned his PhD in Biochemistry at The Ohio State University, an MBA at the Johnson Graduate School of Management at Cornell University, and a BS/MS in Chemistry at Peking University. He has authored 18 papers, including 2 in Nature and 2 in Nature Structural Biology, and holds 15 patents worldwide.
Mo Xu, M.D., Ph.D.
SVP of Clinical Development
Mo Xu is responsible for the company's clinical development strategy and pipeline layout. With a wealth of experience in the pharmaceutical industry, she has held positions at Gemvax (overseas) and several multinational companies, including AstraZeneca, Merck, MSD, Pfizer, as well as the local pharmaceutical company Alphamab Oncology. In these roles, she has served as Vice President of Clinical Development for various innovative drugs, making significant contributions to clinical research and development in fields such as immune-oncology products, ADC products, and anti-cancer vaccines. Her expertise lies in the development of innovative drugs, and she possesses in-depth knowledge of both domestic and international regulatory requirements, treatment guidelines, as well as strategies for immune-oncology development, market access, and product positioning. She has successfully led teams in the completion of multiple innovative drug development projects, both domestically and internationally. She obtained her doctoral degree from Yonsei University in South Korea.